Salt selection improved the developability of an inhaled poorly soluble compound

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-B-048-Monday
• By: TEHLER, Ulrika (AstraZeneca, Pharmaceutical Sciences, Mölndal, Sweden)
• Co-author(s): Ulrika Tehler: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
  Carolyn Stevenson: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
  Martin Lindsjö: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
  Ann-Kristin Ekelund: Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden
  
• Abstract:

  Backgrounds

  Compound A is a poorly soluble compound intended for inhaled treatment of asthma. Initial toxicological evaluation in rodents suggested presence of undissolved material in the lung after repeat dosing.  Compound A as the free form is considered to be a poorly soluble compound with dissolution driven lung retention.

  Aims

  To minimize the
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login